Schneiderman's probe also comes on the heels of news that Minnesota's attorney general, Lori Swanson, has asked Mylan to provide documents that would justify the company having raised the retail price of EpiPens more than 400 percent in recent years, up to more than $600 per two-device pack.
"No child's life should be put at risk because a parent, school, or health-care provider cannot afford a simple, lifesaving device because of a drug-maker's anti-competitive practices," Schneiderman said.
"If Mylan engaged in anti-competitive business practices, or violated antitrust laws with the intent and effect of limiting lower-cost competition, we will hold them accountable," he said.
"Allergy sufferers have enough concerns to worry about — the availability of lifesaving medical treatment should not be one of them. I will bring the full resources of my office to this critical investigation."
Mylan, in an emailed response, said that its EpiPen4Schools program, which has provided more than 700,000 free EpiPens to more than 65,000 participating schools since its inception, "continues to adhere to all applicable laws and regulations."
"There are no purchase requirements for participation in the program, nor have there ever been to receive free EpiPen Auto-Injectors," Mylan said. "Previously, schools who wished to purchase EpiPen Auto-Injectors beyond those they were eligible to receive free under the program could elect to do so at a certain discount level with a limited purchase restriction, but such restriction no longer remains. "
Last week, the company said that it would launch a generic version of the EpiPen, for half the price of that branded product.